Contents



Preface vii

About the Author x

Part 1 A Brief Introduction to RNA Metabolism and Disease 1

Chapter 1 An RNA Primer 3

1.1 What is RNA? 3

Chapter 2 DNA, Chromosomes, and Genes 8

2.1 DNA 101 8

2.2 Where Does DNA Come From? 12

2.3 Genes, Mutations, and Disease 14

Chapter 3	What is RNA?	19
	3.1 RNA Chemistry: The Basics	19
	3.2 How Genes are Decoded — The Central Dogma	23
Chapter 4	DNA Decoded: Messenger RNA	27
	4.1 mRNA and The Genetic Code	27
	4.2 Mutations, Revisited	33
	4.3 Why mRNA?	36
	4.4 mRNA Splicing	39
	4.5 Caps and Tails	42
Chapter 5	How RNA Makes Proteins	47
	5.1 The Ribosome is a Protein-Making Factory	47
	5.2 Transfer RNA	51
	5.3 Putting the Pieces Together: Protein Synthesis	57
	5.4 Conveyor Belts, Brownian Motion, Ratchets, and Engines	63
Chapter 6	Gene Regulation	69
	6.1 The Many Facets of Gene Regulation	69
	6.2 The Life History of an mRNA, from Birth to Death	72
	6.3 Proteins are Regulated Too	77

6.4 All Biological Processes Involve Gene Regulation Pathways 78

Chapter 7 Small Regulatory RNAs 80
7.1 Noncoding RNAs are Everywhere 80
7.2 The Discovery of microRNAs 81
7.3 How microRNAs are Made 88
7.4 The Discovery of Small Interfering RNAs 92
7.5 RNA Interference and its Biological Role 95
7.6 How do microRNAs and siRNAs Find and Regulate Specific mRNAs? 98

Part 2 Emerging RNA Therapeutics 101

Chapter 8 Biologicals vs. Chemicals 103
8.1 Introduction to Biological Therapeutics 103
8.2 Biological Drugs vs. Chemical Drugs 109
8.3 An Introduction to RNA Therapeutics 113

Chapter 9 Antisense Oligonucleotide Therapeutics 118
9.1 But first, Spinal Muscular Atrophy 118
9.2 The Genetics of Spinal Muscular Atrophy 122
9.3 Improving the Efficiency of SMN2 Splicing to Treat SMA 125
9.4 Antisense Oligonucleotide Therapeutics 127
9.5 The Example of Nusinersen 131

9.6 Alternatives to Nusinersen in the Treatment of SMA 136
9.7 Evidence of Programmability — the Amazing Story of Milasen 141

Chapter 10 RNAi Therapeutics 146
10.1 Is Gene Silencing a Good Thing? 146
10.2 RNAi from Bench to Bedside 149
10.3 RNAi Mechanism, Revisited 152
10.4 Design Considerations for RNAi Therapeutics 157
10.5 Patisiran, the First RNAi Drug 161
10.6 Other FDA-Approved RNAi Drugs 166
10.7 Challenges and Opportunities in RNAi Therapeutics 172

Chapter 11 mRNA Vaccines 176
11.1 One Man's COVID-19 Story 176
11.2 A Brief History of Vaccines 178
11.3 The Novel Coronavirus Pandemic of 2019 183
11.4 The Betacoronaviridae 185
11.5 Spike Protein 188
11.6 COVID Vaccine Development 191
11.7 Where did mRNA Vaccines Come From? 198
11.8 Post-Pandemic mRNA Vaccines 204
11.9 How Vaccines are Made: Influenza vs. SARS-CoV-2 206

Part 3 RNA-Guided Genome Editing 211

Chapter 12 Rewriting the Genome 213
12.1 Introduction to Genome Editing 213
12.2 DNA Damage and Repair 214
12.3 Targeted Double-Strand DNA Cleavage 221
12.4 Restriction Enzymes 222
12.5 ZFN and TALEN Therapeutics 229
12.6 Viral Genome Integration 233
12.7 Retroviral Gene Therapy in the Clinic 236
12.8 Retroviral Gene Therapy for Sickle Cell Disease 239

Chapter 13 The CRISPR Revolution 241
13.1 Cas9: The Game Changer 241
13.2 Genomes, Genetics, and Yogurt: The History of CRISPR 245
13.3 The Structure and Function of Cas9 248
13.4 Cas9 from Bench-to-Bedside 251
13.5 Other CRISPR-Associated Genes 256

Chapter 14 The Ethics of Genome Editing 262
14.1 The CRISPR Baby Scandal 262
14.2 Somatic vs. Germline Edits, What's the Big Deal? 268
14.3 The Role of Society 272
14.4 The Regulatory Landscape of Germline Genome Editing 273

Chapter 15 The Future of RNA Medicine 277
15.1 Barriers to Everyday RNA 277
15.2 Personalized RNA Medicine 280
15.3 A Future in Peril 282

Bibliography 285
Index 375